Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02185417 · ClinicalTrials.gov registry record · Phase 3
Diuretic Comparison Project
A Phase 3 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 20,723
- Enrollment target
NCT02185417: Completed Phase 3 study, sponsored by VA Office of Research and Development.
NCT02185417 is a Phase 3 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 20,723 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (2588% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02185417, a Phase 3 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20,723 participants
- Enrollment target
Study Summary
The Diuretic Comparison Project aimed to evaluate whether chlorthalidone, as compared with hydrochlorothiazide, would reduce the risk of major nonfatal cardiovascular disease outcomes and non-cancer-related deaths in older patients with hypertension who were receiving hydrochlorothiazide at baseline. The investigators incorporated the pragmatic methods used by the Department of Veterans Affairs (VA) Healthcare System to provide a real-world assessment of the effectiveness of chlorthalidone as compared with hydrochlorothiazide in routine clinical care.
Primary Outcome
Time to study primary outcome was defined as years from randomization to the first occurrence of a composite endpoint, consisting of a nonfatal cardiovascular event or non-cancer related death. Nonfatal cardiovascular events included nonfatal myocardial infarction, stroke, hospitalization for heart failure, or urgent coronary revascularization for unstable angina. For participants who had a primary outcome, time to event was determined as the earliest admission or death date. Ascertainment of st
Interventions
- DRUG Hydrochlorothiazide (HCTZ)
- DRUG Chlorthalidone (CTD)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,723 participants |
| Start Date | 2016-06-15 |
| Est. Completion | 2022-12-29 |
| Phase | Phase 3 |
What the finished NCT02185417 record still lists
NCT02185417 is an interventional study that assigns participants to a tested intervention. Its 20,723 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (2588% higher).
The record links to 0 conditions, and to 2 interventions - of which Hydrochlorothiazide (HCTZ) is the first listed.
NCT02185417 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02185417 about?
NCT02185417 is a clinical study titled "Diuretic Comparison Project". The Diuretic Comparison Project aimed to evaluate whether chlorthalidone, as compared with hydrochlorothiazide, would reduce the risk of major nonfatal cardiovascular disease outcomes and non-cancer-related deaths in older patients with hypertension who were receiving hydrochlorothiazide at baseline...
What is the current status of trial NCT02185417?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20,723 participants. The study started on 2016-06-15. Estimated completion is 2022-12-29.
What interventions are being tested in trial NCT02185417?
The interventions under investigation include: Hydrochlorothiazide (HCTZ) (DRUG), Chlorthalidone (CTD) (DRUG).
Who is sponsoring clinical trial NCT02185417?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02185417's enrollment target sits among peer trials
20,723 9th of 2000 higher than 1,992 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07213531 · 21,000 participants
Enhanced Valves Interventions and Safe AI Generated End Results
- NCT06062342 · 20,400 participants · NA
Five Point Initiative: A Bundled Implementation Strategy to Address the HIV Epidemic in Black Communities
- NCT06047041 · 21,350 participants · NA
Implementation Supports for Improving Identification and Delivery of School-based Mental Health Supports for Middle Schools Students
- NCT00271180 · 20,000 participants
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI